{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Aspirin in PCI; Mavacamten in Nonobstructive Cardiomyopathy; Olezarsen and the Treatment of Hypertriglyceridemia","description":" Dr. Eagle continues in this week\u2019s View to analyze some of the key clinical content presented at the ESC Congress recently held in Spain. Dr. Eagle examines the TARGET-FIRST trial in which P2Y12-inhibitor monotherapy was compared to dual antiplatelet therapy (DAPT) in patients who have undergone percutaneous coronary intervention (PCI).&amp;nbsp; He then analyzes the results of the ODYSSEY-HCM trial which explored mavacamten versus placebo in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the ESSENCE-TIMI 73b study that looked at olezarsen and its potential for lowering triglycerides in moderate hypertriglyceridemia with elevated cardiovascular risk.&amp;nbsp;&amp;nbsp;   &amp;nbsp;Subscribe to Eagle\u2019s Eye View&amp;nbsp;&amp;nbsp;  ","author_name":"Eagle's Eye View: Your Weekly CV Update From ACC.org","author_url":"http:\/\/www.acc.org","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/38241815\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/193124230"}